Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in high‐risk follicular lymphoma, regardless of POD24 status Meeting Abstract
| Authors: | Belada, D.; Falchi, L.; Leppä, S.; Vermaat, J. S.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; Nijland, M.; Merryman, R. W.; Christensen, J. H.; Wahlin, B. E.; Linton, K. M.; Wang, L.; Abbas, A.; Rana, A.; Quadri, S.; Sureda, A. |
| Abstract Title: | Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in high‐risk follicular lymphoma, regardless of POD24 status |
| Meeting Title: | 17th International Conference on Malignant Lymphoma (ICML) |
| Journal Title: | Hematological Oncology |
| Volume: | 41 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Jun 13-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2023-06-01 |
| Start Page: | 125 |
| End Page: | 127 |
| Language: | English |
| DOI: | 10.1002/hon.3163_84 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 084 -- Source: Cinahl |
